A Nasdaq Hearings Panel granted Silexion continued listing, subject to conditions. The company must complete a $2.5 million private placement by December 4, 2026, and a public offering of at least $5 million by March 31, 2027.
SLXN · Silexion Therapeutics Corp · Documents
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, we had cash and cash equivalents of $4.8 million. Based on our current cash balance, as well as our history of operating losses and negative cash flows from operations, combined with our anticipated use of cash to, among other things, (i) fund the clinical development of SIL204, (ii) identify and develop new product candidates, and (iii) seek approval for SIL204 and any other product candidates we may develop, our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and nine-month periods ended September 30, 2026 included in this quarterly report, but rather, for only several months from the filing date of this quarterly report, under our current business plan, as a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Silexion Therapeutics Corp dosed its first patient with SIL204 on September 30, 2026 in a Phase 2/3 pancreatic cancer trial at Tel Aviv Sourasky Medical Center. Cash and cash equivalents were $4.8 million.
Silexion Therapeutics Corp dosed its first SIL204 Phase 2/3 patient in locally advanced pancreatic cancer, while awaiting a Nasdaq listing decision. The company reported an $8.8 million nine-month net loss and said cash would fund only several months.
Silexion Therapeutics Corp completed a 1-for-24 reverse share split effective after trading on November 10, 2026, leaving 21,495,833 authorized ordinary shares at $3.24 par value and adjusting warrants to 1/24 share each at $372,600.00 per share.
Silexion Therapeutics Corp will conduct a 1-for-24 reverse share split after market close on November 10, 2026, with split-adjusted Nasdaq Capital Market trading beginning November 11, 2026 under ticker “SLXN”; par value will rise from $0.135 per share to $3.24 per share.
Silexion Therapeutics registers resale of up to 8,813,531 ordinary shares by selling shareholders, including 1,414,266 note shares and 740,224 commercial shares. The shares stem from warrant inducement at $0.2603 per share, conversion of a Moringa Sponsor note and payment to LifeSci for services. The company receives no resale proceeds but may receive cash from warrant exercises.
Silexion Therapeutics shareholders approved increasing authorized share capital by 500,000,000 ordinary shares, to 515,900,000, and a reverse split range of 1-for-15 to 1-for-25, with the Board setting 1-for-24.
Silexion Therapeutics Corp (Nasdaq: SLXN) adjourned its October 19, 2026 extraordinary general meeting to October 26, 2026, to vote on increasing authorized share capital by 500,000,000 ordinary shares and authorizing a reverse share split of 1-for-15 to 1-for-25 to regain Nasdaq compliance.
Silexion Therapeutics Corp will ask shareholders on October 19, 2026 to approve adding 500,000,000 authorized ordinary shares and authorizing a reverse split from not less than 1-for-15 to not more than 1-for-25, both intended to support Nasdaq compliance.
Silexion Therapeutics Corp dosed the first patient worldwide in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, beginning an approximately 18-patient safety run-in followed by an approximately 166-patient randomized expansion.
Silexion Therapeutics Corp expects approximately $0.84 million in gross proceeds from 3,216,928 warrant exercises at $0.2603 per share and will issue 3,216,928 Series F warrants and 3,216,928 Series G warrants to purchase up to 6,433,856 ordinary shares at $0.2603 per share.
Silexion Therapeutics Corp reported positive preclinical findings that SIL204 uses circulating lipoproteins for cellular uptake and dose-dependent mutant KRAS silencing; lipid depletion reduced knockdown (P < 0.001), while physiological lipid levels enabled uptake without artificial carriers.
On September 25, 2026, Nasdaq notified Silexion Therapeutics Corp of a bid-price deficiency after 30 consecutive business days below $1.00 per share under Listing Rule 5550(a)(2). The hearings panel will consider Nasdaq Capital Market listing; shares and warrants continue trading.
Silexion Therapeutics Corp shareholders will vote on adding 500,000,000 authorized shares and authorizing a reverse split between 1-for-15 and 1-for-25 to restore Nasdaq compliance with $1.00 minimum bid price and $2.5 million shareholders’ equity requirements.
At its September 23, 2026 meeting, Silexion Therapeutics Corp shareholders rejected a 175,000,000-share authorized capital increase and authorization of a 1-for-15 reverse share split.